Patents by Inventor Helene Margaret Finney

Helene Margaret Finney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY MOLECULES WHICH BIND CD45
    Publication number: 20230287134
    Abstract: The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.
    Type: Application
    Filed: January 11, 2023
    Publication date: September 14, 2023
    Inventors: Helene Margaret FINNEY, Stephen Edward RAPECKI, Kerry Louise TYSON, Michael John WRIGHT
  • Antibody molecules which bind CD45
    Patent number: 11692041
    Abstract: The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: July 4, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Kerry Louise Tyson, Michael John Wright
  • Anti-FcRn Antibodies
    Publication number: 20230074381
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: June 1, 2022
    Publication date: March 9, 2023
    Applicant: UCB Biopharma SRL
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • ANTIBODY MOLECULES WHICH BIND CD22
    Publication number: 20230065921
    Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
    Type: Application
    Filed: August 23, 2022
    Publication date: March 2, 2023
    Inventors: Helene Margaret FINNEY, Stephen Edward RAPECKI, Kerry Louise TYSON, Michael John WRIGHT
  • Antibody molecules which bind CD22
    Patent number: 11472879
    Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: October 18, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Kerry Louise Tyson, Michael John Wright
  • Anti-FcRn antibodies
    Patent number: 11384148
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: July 12, 2022
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • ANTIBODIES SPECIFIC TO FCRN
    Publication number: 20220162311
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: December 9, 2021
    Publication date: May 26, 2022
    Applicant: UCB BIOPHARMA SPRL
    Inventors: Paul Alan ATHERFOLD, Thomas Allen CESKA, Helene Margaret FINNEY, Lara KEVORKIAN, Kaushik SARKAR, Bryan John SMITH, Kerry Louise TYSON
  • Molecules with specificity for CD79 and CD22
    Patent number: 11261252
    Abstract: The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: March 1, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson
  • Antibodies specific to FCRN
    Patent number: 11220547
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: January 11, 2022
    Assignee: UCB Biopharma SPRL
    Inventors: Paul Alan Atherfold, Thomas Allen Ceska, Helene Margaret Finney, Lara Kevorkian, Kaushik Sarkar, Bryan John Smith, Kerry Louise Tyson
  • Method employing bispecific protein complex
    Patent number: 10954312
    Abstract: The present invention is directed to a method of controlling and directing cells, for example to stimulate an immune response, inhibit an immune response, direct tissue regeneration or prevent tissue damage for therapeutic activity through the use of heterodimerically-tethered bispecific protein complex of formula A-X:Y-B. Component A may present X on the surface of a cell, may bind a protein (including a marker) expressed on the surface of an effector cell, or A-X is expressed on the surface of an effector cell, whilst B is specific to an epitope on target cell or tissue of interest. X:Y is a heterodimeric-tether which is formed by a binding interaction between X and Y, which together with A and B assists and effects the controlling and directing of the selected cells.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: March 23, 2021
    Assignee: UCB BIOPHARMA SRL
    Inventor: Helene Margaret Finney
  • Molecules with specificity for CD45 and CD79
    Patent number: 10774152
    Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: September 15, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson
  • Molecules with specificity for CD45 and CD79
    Patent number: 10730952
    Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: August 4, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson
  • ANTIBODY MOLECULES WHICH BIND CD22
    Publication number: 20200157215
    Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
    Type: Application
    Filed: January 31, 2020
    Publication date: May 21, 2020
    Inventors: Helene Margaret FINNEY, Stephen Edward RAPECKI, Kerry Louise TYSON, Michael John WRIGHT
  • Antibody molecules which bind CD79
    Patent number: 10618957
    Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD79, said binding domain comprising SEQ ID NO: 1, 2, 3 or 4, and/or SEQ ID NO: 5, 6 and 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: April 14, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Kerry Louise Tyson, Michael John Wright
  • Antibody molecules which bind CD22
    Patent number: 10590197
    Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: March 17, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Kerry Louise Tyson, Michael John Wright
  • MOLECULES WITH SPECIFICITY FOR CD79 AND CD22
    Publication number: 20200024346
    Abstract: The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.
    Type: Application
    Filed: July 16, 2019
    Publication date: January 23, 2020
    Inventors: Helene Margaret FINNEY, Stephen Edward RAPECKI, Michael John WRIGHT, Kerry Louise TYSON
  • MOLECULES WITH SPECIFICITY FOR CD45 AND CD79
    Publication number: 20190359713
    Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.
    Type: Application
    Filed: July 3, 2019
    Publication date: November 28, 2019
    Inventors: HELENE MARGARET FINNEY, STEPHEN EDWARD RAPECKI, MICHAEL JOHN WRIGHT, KERRY LOUISE TYSON
  • BISPECIFIC FORMAT SUITABLE FOR USE IN HIGH-THROUGH-PUT SCREENING
    Publication number: 20190322739
    Abstract: The present disclosure relates to a novel bispecific protein complex and a method of using the complexes to screen for synergistic or novel biological function. The bispecific format is particularly suitable for high-throughput screening because all of its components can be expressed from cells as individual units and the units can be assembled simply by mixing without employing conjugation or coupling chemistry.
    Type: Application
    Filed: May 2, 2019
    Publication date: October 24, 2019
    Inventors: Helene Margaret FINNEY, Stephen Edward RAPECKI, Michael John WRIGHT
  • ANTIBODIES SPECIFIC TO FCRN
    Publication number: 20190270811
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: March 12, 2019
    Publication date: September 5, 2019
    Inventors: Paul Alan ATHERFOLD, Thomas Allen CESKA, Helene Margaret FINNEY, Lara KEVORKIAN, Kaushik SARKAR, Bryan John SMITH, Kerry Louise TYSON
  • Anti-FcRn Antibodies
    Publication number: 20190248890
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: February 8, 2019
    Publication date: August 15, 2019
    Applicant: UCB Biopharma SPRL
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold